Literature DB >> 35836853

Efficacy of adenosylmethionine combined with Si Mo Tang in treatment of neonatal jaundice.

Ling Li1, Jingqun Wang1, Shuxia Geng1, Fang Liu2, Lili Ping3, Xiaohong Gu4, Xueai Fan5, Mei Yang6, Lixia Liang7, Wei Guo1.   

Abstract

OBJECTIVE: To investigate the efficacy of S-adenosylmethionine (SAM-e) combined with Si Mo Tang in the treatment of neonatal jaundice and its effect on liver function, cardiac enzymes, immune function, serum transferrin (TRF) and C-reactive protein (CRP) levels.
METHODS: The clinical data of 149 infants with neonatal jaundice were collected retrospectively. The infants were grouped according to the treatment methods. All neonates were treated with blue light phototherapy. Besides, group A was treated with SAM-e, group B was treated with Si Mo Tang, and group C was treated with SAM-e combined with Si Mo Tang. The treatment efficacy, serum bilirubin level, neonatal behavioral neurological assessment (NBNA) score, liver function, cardiac enzymes, immune function, serum TRF and CRP level were compared among the three groups before and after treatment.
RESULTS: The total effective rate of treatment in group C was 96.00%, which was higher than group A (73.47%) and group B (78.00%) (P < 0.05), but no significant difference was observed between groups A and B (P > 0.05). Compared with groups A and B, group C had higher NBNA scores, lower serum bilirubin levels, and lower serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), creatine kinase (CK) and creatine kinase-MB (CK-MB) levels (all P < 0.05); however, there was no statistical differences in NBNA scores, serum bilirubin levels, serum AST and ALT, LDH, CK and CK-MB levels between group A and group B (all P > 0.05). Compared with groups A and B, group C showed higher CD4+, CD4+/CD8+, TRF levels and lower serum CRP levels (P < 0.05), while there was no statistical differences in CD4+, CD4+/CD8+, CD8+, TRF levels and serum CRP levels between group A and group B (all P > 0.05).
CONCLUSION: SAM-e combined with Si Mo Tang promoted the regression of jaundice, improved liver function, neurodevelopmental conditions and the myocardial enzyme spectrum, reduced the level of inflammation, and improved the immunity of newborns with neonatal jaundice. AJTR
Copyright © 2022.

Entities:  

Keywords:  Adenosylmethionine; C-reactive protein; Si Mo Tang; cardiac enzymes; immune function; liver function; neonatal jaundice; transferrin

Year:  2022        PMID: 35836853      PMCID: PMC9274584     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  29 in total

Review 1.  Breakthrough cancer pain (BTcP) management: a review of international and national guidelines.

Authors:  Andrew Neil Davies; Frank Elsner; Marilène Jeanne Filbet; Josep Porta-Sales; Carla Ripamonti; Daniele Santini; Kath Webber
Journal:  BMJ Support Palliat Care       Date:  2018-06-06       Impact factor: 3.568

2.  Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy.

Authors:  V T Ferrero; M M Oset; J P Masferrer; E H Pardo; E J Sorolla; S C Largo
Journal:  Clin Transl Oncol       Date:  2019-04-05       Impact factor: 3.405

3.  Nitrous oxide/oxygen mixture for analgesia in adult cancer patients with breakthrough pain: A randomized, double-blind controlled trial.

Authors:  Q Liu; L-L Gao; Y-L Dai; Y-X Li; Y Wang; C-F Bai; G-X Mu; X-M Chai; W-J Han; L-J Zhou; Y-J Zhang; L Tang; J Liu; J-Q Yu
Journal:  Eur J Pain       Date:  2017-12-11       Impact factor: 3.931

Review 4.  Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.

Authors:  Jeannine M Brant; Barbara B Rodgers; Eva Gallagher; Thiruppavai Sundaramurthi
Journal:  Clin J Oncol Nurs       Date:  2017-06-01       Impact factor: 1.027

5.  Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.

Authors:  Winfried Häuser; Patrick Welsch; Petra Klose; Lukas Radbruch; Mary-Ann Fitzcharles
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

6.  Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.

Authors:  Sebastiano Mercadante; Augusto Caraceni; Francesco Masedu; Teresa Scipioni; Federica Aielli
Journal:  Oncologist       Date:  2019-12-20

7.  Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm.

Authors:  Jaume Canal-Sotelo; Javier Trujillano-Cabello; Philip Larkin; Núria Arraràs-Torrelles; Ramona González-Rubió; Mariona Rocaspana-Garcia; Eva Barallat-Gimeno
Journal:  BMC Palliat Care       Date:  2018-05-28       Impact factor: 3.234

8.  Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.

Authors:  Jordi Guitart; María Isabel Vargas; Vicente De Sanctis; Jordi Folch; Rafael Salazar; José Fuentes; Joan Coma; Julia Ferreras; Jordi Moya; Albert Tomás; Pere Estivill; Francisco Rodelas; Antonio Javier Jiménez; Almudena Sanz
Journal:  Drugs R D       Date:  2018-06

9.  Development and Testing of a Mobile App for Pain Management Among Cancer Patients Discharged From Hospital Treatment: Randomized Controlled Trial.

Authors:  Jing Yang; Lizhu Weng; Zhikui Chen; Hongfu Cai; Xiaoyan Lin; Zhijian Hu; Na Li; Bijuan Lin; Bin Zheng; Qian Zhuang; Bin Du; Zhiyuan Zheng; Maobai Liu
Journal:  JMIR Mhealth Uhealth       Date:  2019-05-29       Impact factor: 4.773

10.  Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study.

Authors:  Arturo Cuomo; Marco Cascella; Cira Antonietta Forte; Sabrina Bimonte; Gennaro Esposito; Stefano De Santis; Luigi Cavanna; Flavio Fusco; Mario Dauri; Silvia Natoli; Marco Maltoni; Alessandro Morabito; Rocco Domenico Mediati; Vito Lorusso; Sandro Barni; Giampiero Porzio; Sebastiano Mercadante; Anna Crispo
Journal:  J Clin Med       Date:  2020-04-02       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.